Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease
P Rolan, MR Hutchinson… - Expert opinion on …, 2009 - Taylor & Francis
P Rolan, MR Hutchinson, KW Johnson
Expert opinion on pharmacotherapy, 2009•Taylor & FrancisIbudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed
for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-
inflammatory activity in both the peripheral immune system and in the CNS via glial cell
attenuation. This CNS-directed anti-inflammatory activity is of potential use in the treatment
of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by
decreasing opioid tolerance, withdrawal and reinforcement. Its suitable pharmacokinetics …
for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-
inflammatory activity in both the peripheral immune system and in the CNS via glial cell
attenuation. This CNS-directed anti-inflammatory activity is of potential use in the treatment
of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by
decreasing opioid tolerance, withdrawal and reinforcement. Its suitable pharmacokinetics …
Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in the CNS via glial cell attenuation. This CNS-directed anti-inflammatory activity is of potential use in the treatment of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by decreasing opioid tolerance, withdrawal and reinforcement. Its suitable pharmacokinetics and generally good tolerability make it a promising potential treatment for these conditions.
Taylor & Francis Online